PharmaOnco™ Jurkat-Tg(Human LAG3)-NFAT Luc Reporter Cell Line, Single Clone (CAT#: ITS-0822-HMM177)

Creative Biolabs offers Jurkat-Tg(Human LAG3)-NFAT Luc reporter cell line which the LAG3 gene stably expressed in NFAT Luc reporter Jurkat cells.

Jurkat-Tg(Human LAG3)-NFAT Luc reporter cell line is a genetically modified cell line derived from Jurkat cells that have been engineered to express human LAG3 (lymphocyte-activation gene 3) and have a luciferase reporter gene under the control of the NFAT (nuclear factor of activated T cells) promoter. This cell line is commonly used in research to study the role of LAG3 in T cell activation and immune response.

Consistent gene expression;
Reliability and reproducibility;

Functional assay

LAG3

Human

Jurkat

GenBank Accession # NM_002286

The Lymphocyte-activation gene 3 (LAG3) is a protein that plays a role in regulating the immune response. It is a cell surface molecule that is expressed on activated T cells, regulatory T cells, and natural killer (NK) cells. LAG3 acts as an immune checkpoint molecule, similar to other checkpoint proteins like PD-1 and CTLA-4, and plays a role in regulating the activation and function of T cells. Binding of LAG3 to its ligands, such as MHC class II molecules, leads to inhibition of T cell proliferation and cytokine production, as well as promoting immune tolerance. Research has suggested that LAG3 may be a potential target for cancer immunotherapy, as blocking LAG3 can enhance anti-tumor immune responses. Studies are ongoing to investigate the potential of targeting LAG3 in cancer treatment.